Model for end-stage liver disease (MELD) and allocation of donor livers
- PMID: 12512033
- DOI: 10.1053/gast.2003.50016
Model for end-stage liver disease (MELD) and allocation of donor livers
Abstract
Background & aims: A consensus has been reached that liver donor allocation should be based primarily on liver disease severity and that waiting time should not be a major determining factor. Our aim was to assess the capability of the Model for End-Stage Liver Disease (MELD) score to correctly rank potential liver recipients according to their severity of liver disease and mortality risk on the OPTN liver waiting list.
Methods: The MELD model predicts liver disease severity based on serum creatinine, serum total bilirubin, and INR and has been shown to be useful in predicting mortality in patients with compensated and decompensated cirrhosis. In this study, we prospectively applied the MELD score to estimate 3-month mortality to 3437 adult liver transplant candidates with chronic liver disease who were added to the OPTN waiting list at 2A or 2B status between November, 1999, and December, 2001.
Results: In this study cohort with chronic liver disease, 412 (12%) died during the 3-month follow-up period. Waiting list mortality increased directly in proportion to the listing MELD score. Patients having a MELD score <9 experienced a 1.9% mortality, whereas patients having a MELD score > or =40 had a mortality rate of 71.3%. Using the c-statistic with 3-month mortality as the end point, the area under the receiver operating characteristic (ROC) curve for the MELD score was 0.83 compared with 0.76 for the Child-Turcotte-Pugh (CTP) score (P < 0.001).
Conclusions: These data suggest that the MELD score is able to accurately predict 3-month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers.
Comment in
-
MELD: the answer or just more questions?Gastroenterology. 2003 Jan;124(1):251-4. doi: 10.1053/gast.2003.50031. Gastroenterology. 2003. PMID: 12512049 No abstract available.
-
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer.Gastroenterology. 2003 Sep;125(3):992-3; author reply 994-5. doi: 10.1016/s0016-5085(03)01149-1. Gastroenterology. 2003. PMID: 12974261 No abstract available.
-
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer.Gastroenterology. 2003 Sep;125(3):993-4; author reply 994-5. doi: 10.1016/s0016-5085(03)01147-8. Gastroenterology. 2003. PMID: 12974262 No abstract available.
Similar articles
-
Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation.BMC Gastroenterol. 2009 Sep 25;9:72. doi: 10.1186/1471-230X-9-72. BMC Gastroenterol. 2009. PMID: 19778459 Free PMC article.
-
Application of a continuous disease severity score to the OPTN liver waiting list.Clin Transpl. 2001:19-24. Clin Transpl. 2001. PMID: 12211782
-
Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?Transplant Proc. 2008 Jul-Aug;40(6):1906-9. doi: 10.1016/j.transproceed.2008.05.072. Transplant Proc. 2008. PMID: 18675085
-
Is the model of end-stage liver disease (MELD) valid in Israel? A critical analysis of liver transplant waiting list mortality.Isr Med Assoc J. 2006 Sep;8(9):605-9. Isr Med Assoc J. 2006. PMID: 17058408
-
Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond.Liver Int. 2008 May;28(5):606-13. doi: 10.1111/j.1478-3231.2008.01727.x. Liver Int. 2008. PMID: 18433390 Review.
Cited by
-
Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.Can Liver J. 2018 Dec 25;1(4):156-217. doi: 10.3138/canlivj.2018-0008. eCollection 2018 Fall. Can Liver J. 2018. PMID: 35992619 Free PMC article.
-
Transjugular intrahepatic portosystemic shunt for the treatment of refractory ascites: A population-based cohort study.Can Liver J. 2020 Nov 17;3(4):334-347. doi: 10.3138/canlivj-2020-0002. eCollection 2020 Fall. Can Liver J. 2020. PMID: 35990506 Free PMC article.
-
Indocyanine Green Retention Test as a Predictor of Postoperative Complications in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.Ther Clin Risk Manag. 2022 Aug 2;18:761-772. doi: 10.2147/TCRM.S363849. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 35941916 Free PMC article.
-
A creatinine-based model for predicting recurrent bleeding after modified percutaneous transhepatic variceal embolization in patients with cirrhosis.J Interv Med. 2022 Mar 26;5(2):95-102. doi: 10.1016/j.jimed.2022.03.007. eCollection 2022 May. J Interv Med. 2022. PMID: 35936666 Free PMC article.
-
MELIF, a Fully Automated Liver Function Score Calculated from Gd-EOB-DTPA-Enhanced MR Images: Diagnostic Performance vs. the MELD Score.Diagnostics (Basel). 2022 Jul 20;12(7):1750. doi: 10.3390/diagnostics12071750. Diagnostics (Basel). 2022. PMID: 35885653 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
